Health

Philips pitches Azurion software while 3,000 of its cath lab systems sit on the FDA recall list

The same week Philips launched UniGuide 3D Live Guidance on Azurion, the FDA logged a Class 2 recall covering more than 3,000 Azurion systems over off-spec solid-state drives, with repairs starting in December. Q3 results land with earnings per share expected at 33 cents, and the service bill arrives in Q4.

Vincent JiangVincent Jiang · 3 min read
Share
A Philips interventional fluoroscopy system, a C-arm over a patient table with ceiling-mounted monitors, installed in a hospital cath lab.
1 / 6Slide 1 of 6
A Philips interventional fluoroscopy system in a hospital cath lab. Azurion, the company's flagship line of these systems, is on the FDA recall list over off-spec solid-state drives, with repairs starting in December.

Two headlines, one platform, one week

Philips−0.74% — Philips, down 0.74 percent as of its last quote, the Netherlands-based health-technology company, is selling hospitals a software story on Azurion, its flagship line of interventional fluoroscopy systems, the real-time X-ray machines used in the cath lab, the cardiac catheterization room where these procedures happen.

On October 29 it launched UniGuide 3D Live Guidance in Europe and other CE-marked markets, meaning approved for sale under the EU's CE conformity mark, a software layer that pulls pre-procedural CT planning into the live cath lab workflow 3. It is CE marked and on sale since October 23, built "on the foundation of the Philips Azurion platform." 3

Then the FDA log caught up

That same week, the FDA database logged a Class 2 recall on Azurion S, initiated by Philips Medical Systems Nederland on October 6, 2026 2. The cause, in the agency's words: solid-state drives "not specified in the Medical Device File may have been installed in various PCs," risking "loss of imaging functionality or motorized movement, a blank or black display, and/or the inability to store newly acquired images or access previously acquired images." 2 Trade press counted the fleet at more than 3,000 systems. 1

Clinicians in surgical caps watch live fluoroscopic coronary images on a large display during a cardiac catheterization procedure.
Live imaging during a cardiac catheterization procedure. The recall's stated risk includes losing the ability to store newly acquired images or access previously acquired ones, which is why the affected systems run under manual workarounds until repairs. · Navy Medicine via Wikimedia Commons

Third entry on the same fleet this year

This is the third FDA Class 2 event to touch the platform in 2026 145. On April 30 Philips initiated recall Z-2258-2026 over hard drives in Azurion and Allura PCs that "may show a decrease in performance as they age," which can cause loss of imaging functionality; the record lists 3,069 units, 872 in the United States, with drive replacement expected to start in September 2026. 4

In May, Radiology Business reported nearly 10,000 Allura and Azurion systems added to the FDA list over X-ray tube cooling hoses that can degrade and leak oil, with Philips replacing components from the first quarter of 2027. 5 The October SSD recall completes the set.

Keep using it, and the fixes start in December

The FDA record for the SSD action shows Philips told consignees the systems may continue in use under manual workarounds: handgrips and brake controls for repositioning, rotation only for floor-mounted systems. Philips "will inspect all systems in scope and replace SSDs," with implementation "in December 2026," and the record lists worldwide distribution. 2

Radiology Business reports Philips intends corrections to begin in December, with field representatives coordinating repairs. 1 The FDA's ledger is filed per model: the record fetched for one model, the Azurion S, lists a single unit, and the 3,000-plus total is Radiology Business's count across the family of records. 12

Three recall events hit Philips' fluoroscopy fleet in 2026

  • Estimate
0 systems2,000 systems4,000 systems6,000 systems8,000 systems10,000 systemsCooling hoses, May10,000 systemsAging hard drives, Apr 303,069 systemsOff-spec SSDs, Oct 63,000 systems
Data
Value
Cooling hoses, May (estimate)10,000 systems
Aging hard drives, Apr 303,069 systems
Off-spec SSDs, Oct 6 (estimate)3,000 systems
Units in commerce per recall event, 2026: the April hard drive figure is the FDA recall record's own count (3,069 units, 872 in the United States); the cooling hose figure is Radiology Business reporting 'nearly 10,000' Allura and Azurion systems, added to the FDA list on May 21 after Philips sent correction letters in late April; the SSD figure is Radiology Business's count of more than 3,000 Azurion systems across the FDA's per-model records. Sources: FDA Class 2 recall records Z-2258-2026 and Z-0300-2027, Radiology Business, May 27, 2026, and October 29, 2026.1,4,5

Two readings of the same repair schedule

The benign reading: Class 2 recalls cover issues with the potential to cause harm where the probability of serious consequences is remote. 5 These are commodity storage parts, not the imaging chain itself, and replacing them is standard field service work. The harder reading: field engineers walking into thousands of cath labs from December, on the flagship platform Philips is asking hospitals to buy software onto, in the quarter its results land. Install pace and service margins are where that friction shows, if it shows.

What to watch when Q3 lands

Q3 results are imminent, with consensus at earnings per share of 33 cents expected. 6 Watch the service commentary and Q4 guidance for the December repair wave 12. Note what the launch release itself concedes: UniGuide is not available for sale in the United States, 3 so the FDA-listed American fleet sits outside the software story's first market. Philips gets the launch press coverage this week; the repair visits on the same machines start in December, and Q3 results will show whether they dent service margins or install pace 3.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading PHG

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Novo's Wegovy pill inherits a $32 billion franchise as a judge declines to block Lilly's ads

    A federal judge in Trenton declined on October 26 to block Eli Lilly's obesity-drug ads without ruling on their merits, and three days later Lilly printed 39% revenue growth built on price cuts. Novo Nordisk reports on November 4 with its pill carrying the load.

    Health

    OpenAI makes UK startup Anima its healthcare showcase as patients call the same bot a wall to care

    OpenAI's October 23 customer story hands UK startup Anima a vendor endorsement just as it enters the US and Australia. The 75% wait cut is Anima's own measurement, and this month Wantage patients called the same bot a wall to care.

    Health

    Butterfly Network's record quarter ran on milestone money, and its own Q4 guide says so

    Butterfly Network beat every mark this morning, but the filings show the growth came from chip licensing, not the probe business, and the company's own fourth-quarter guide says that money does not repeat. At 17.6 times sales, the market is paying subscription prices for milestone money.

    Health

    GE HealthCare beat and raised, then filed the exit of the PCS chief to a rival's top job

    The same 8-K filed October 28, 2026, carried a quarter strong enough to raise guidance and the resignation of Jeannette Bankes, who leaves the Patient Care Solutions segment five days after its margin jumped 480 basis points. Investors have to price both at once.

    Health

    Eli Lilly's retatrutide beat Ozempic head-to-head: 20.9% weight loss vs 9.4%, before Novo Nordisk reports

    Lilly's retatrutide beat Ozempic's highest approved dose on blood sugar and cut more than twice the weight in a 1,298-patient Phase 3, published two days before Lilly's Q3 report. Novo's flagship franchise just lost its standard-of-care argument inside the window where payers and investors are repricing it.

    Health

    Bunsen now runs 80% of Schrödinger's own modeling jobs, and November 4 shows if customers pay for it

    Schrödinger's Bunsen agent now runs roughly 80 percent of the computational jobs on the company's own cluster, a reversal for a CEO who called AI drug discovery nonsense in 2024. With full launch due by year-end and Q3 results on Nov. 4, the throughput-licensing model is about to be tested on customers, not just insiders.

    Get the newsletter

    The day's AI and market news, in your inbox every weekday.